The differences found between these two reports could have been reliant on the TNFR1 inhibition approach (hepatic vs. systemic inhibition), suggesting that extra-hepatic players might also have an important role in NAFLD development. Here, TNFRSF1A is linked to metabolic dysfunction-associated steatotic liver disease.